SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Feb 2022 Evaluate
The company witnessed a 17.20% growth in the revenue at Rs. 4430.01 millions for the quarter ended December 2021 as compared to Rs. 3779.82 millions during the year-ago period.The Total Profit for the quarter ended December 2021 of Rs. 97.32 millions grew from Rs.-80.56 millionsOperating profit for the quarter ended December 2021 rose to 471.19 millions as compared to 334.28 millions of corresponding quarter ended December 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 4430.01 3779.82 17.20 11920.23 11941.43 -0.18 15428.96 23631.57 -34.71
Other Income 5.30 6.55 -19.08 107.73 17.03 532.59 27.22 40.06 -32.05
PBIDT 471.19 334.28 40.96 1204.61 826.88 45.68 1129.49 2223.33 -49.20
Interest 176.24 306.34 -42.47 613.78 863.87 -28.95 1120.32 1258.23 -10.96
PBDT 294.95 27.94 955.65 590.83 -36.99 -1697.27 -243.98 965.10 -125.28
Depreciation 142.78 151.01 -5.45 427.10 452.45 -5.60 602.53 607.66 -0.84
PBT 152.17 -123.07 -223.65 163.73 -489.44 -133.45 -846.51 357.44 -336.83
TAX 54.85 -42.51 -229.03 27.10 -167.56 -116.17 -115.04 56.83 -302.43
Deferred Tax 54.85 -42.51 -229.03 27.10 -167.56 -116.17 -200.90 40.21 -599.63
PAT 97.32 -80.56 -220.80 136.63 -321.88 -142.45 -731.47 300.61 -343.33
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 9.18 7.72 19.04 10.11 6.92 45.94 6.41 8.42 -23.95

Nectar Lifesciences Share Price

12.20 -0.06 (-0.49%)
16-Apr-2026 10:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1692.15
Dr. Reddys Lab 1220.50
Cipla 1229.20
Zydus Lifesciences 938.90
Lupin 2318.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×